研究目的
To evaluate the efficacy of intravitreal aflibercept (IVA) in vascular and macular maturation in neonates with type 1 retinopathy of prematurity (ROP) and aggressive posterior retinopathy of prematurity (APROP).
研究成果
Intravitreal aflibercept monotherapy is effective for type I ROP and APROP, with low re-treatment rates and favorable vascular and macular maturation outcomes.
研究不足
The study is retrospective and has a limited sample size. The long-term effects of IVA monotherapy beyond 12 months were not evaluated.
1:Experimental Design and Method Selection:
The study is a retrospective study evaluating the efficacy of IVA in neonates with type 1 ROP or APROP using FA and OCT.
2:Sample Selection and Data Sources:
Thirty-six eyes of 18 patients with type 1 ROP or APROP in zone I or posterior zone II were enrolled.
3:List of Experimental Equipment and Materials:
Fluorescein angiography (FA) with the RetCam III Imaging System and optical coherence tomography (OCT) with handheld probe spectral domain optical coherence tomography (SD OCT) systems (Envisu C2300 and R2310; Bioptigen, Inc.).
4:Experimental Procedures and Operational Workflow:
IVA injection was performed under topical anesthesia. FA and OCT were performed at baseline and after IVA injection at specified intervals.
5:Data Analysis Methods:
Vascular and macular changes were analyzed using FA and OCT images.
独家科研数据包,助您复现前沿成果,加速创新突破
获取完整内容